Objectives: Levosimendan is a calcium sensitizer that is used as positive inotropic drug in acute decompensated heart failure. An increased incidence of atrial fibrillation after levosimendan-treatment was observed in clinical and experimental studies. Due to the limited range of antiarrhythmic drugs, the aim of the present study was to assess potential antiarrhythmic effects of ranolazine in levosimendan-pretreated isolated rabbit hearts. Methods: Twelve rabbit hearts were excised and retrogradely perfused employing the Langendorff setup. Left and right atrial catheters were used to record monophasic action potentials and to obtain cycle length-dependent atrial action potential durations (aAPD90) and effective refractory periods (aERP). After obtaining baseline data, 0.5 µmol/L levosimendan was infused. Subsequently, 10 µmol/L ranolazine was administered. Results: Infusion of levosimendan led to a reduction of aAPD90 (–9 ms, p < 0.05) and aERP (–13 ms, p < 0.05). Additional treatment with ranolazine prolonged aAPD90 (+23 ms, p < 0.01) and aERP (+30 ms, p < 0.05). Under baseline conditions, a predefined pacing protocol induced 77 episodes of atrial fibrillation. Infusion of levosimendan enhanced the vulnerability to atrial fibrillation (132 episodes, p = 0.14). Further treatment with ranolazine had a significant antiarrhythmic effect (61 episodes, p < 0.05). Conclusions: In this study, ranolazine seems to prevent atrial fibrillation in levosimendan-pretreated hearts. Underlying mechanism is a prolongation of atrial repolarization and aERP.

Keywords:
Atrial fibrillation, Levosimendan, Ranolazine
1.
Farmakis D, Alvarez J, Gal TB, Brito D, Fedele F, Fonseca C, et al: Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol 2016; 222: 303–312.
2.
Gong B, Li Z, Yat Wong PC: Levosimendan treatment for heart failure: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2015; 29: 1415–1425.
3.
Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R: Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol 2012; 17: 125–130.
4.
Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al: Levosimendan vs dobutamine for patients with acute decompensated heart failure: the survive randomized trial. JAMA 2007; 297: 1883–1891.
5.
Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al: Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013; 1: 103–111.
6.
Frommeyer G, Kohnke A, Ellermann C, Dechering DG, Kochhauser S, Reinke F, et al: Acute infusion of levosimendan enhances atrial fibrillation in an experimental whole-heart model. Int J Cardiol 2017; 236: 423–426.
7.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al: 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with eacts. Eur Heart J 2016; 37: 2893–2962.
8.
Gupta T, Khera S, Kolte D, Aronow WS, Iwai S: Antiarrhythmic properties of ranolazine: a review of the current evidence. Int J Cardiol 2015; 187: 66–74.
9.
Frommeyer G, Sterneberg M, Dechering DG, Ellermann C, Bogeholz N, Kochhauser S, et al: Effective suppression of atrial fibrillation by ivabradine: novel target for an established drug? Int J Cardiol 2017; 236: 237–243.
10.
Frommeyer G, Milberg P, Uphaus T, Kaiser D, Kaese S, Breithardt G, et al: Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. Cardiovasc Ther 2013; 31:e63–e71.
11.
Schotten U, Verheule S, Kirchhof P, Goette A: Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011; 91: 265–325.
12.
Rayner-Hartley E, Sedlak T: Ranolazine: a contemporary review. J Am Heart Assoc 2016; 5:e003196.
13.
Frommeyer G, Rajamani S, Grundmann F, Stypmann J, Osada N, Breithardt G, et al: New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia. J Card Fail 2012; 18: 939–949.
14.
Frommeyer G, Schmidt M, Clauss C, Kaese S, Stypmann J, Pott C, et al: Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. Eur J Heart Fail 2012; 14: 1322–1331.
15.
Burashnikov A, Di Diego JM, Barajas-Martinez H, Hu D, Cordeiro JM, Moise NS, et al: Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. Circ Heart Fail 2014; 7: 627–633.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.